Nest-1 is under clinical development by Nested Therapeutics and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nest-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nest-1 overview

 NST-628 is under development for the treatment of solid tumor, non-small lung cancer, central nervous system (CNS) tumor like glioma and melanoma. The drug candidate is a non-degrading, molecular glue that acts by targeting RAS/MAPK pathway. It is administered through oral route.

Nested Therapeutics overview

Nested Therapeutics (Nested) is a biotechnology company. It discovers and develops novel small-molecule precision medicine therapies for cancer treatment by using mutation clusters to identify druggable pockets. The company’s lead product candidate, NEST-1, a non-degrading molecule glue that targets multiple critical components in the RAS/MAPK pathway. Nested’s pipeline also includes NEST-2, NEST-3, NEST-4, and NEST-5 drug candidates. The company utilizes its proprietary insightful drug discovery platform that maps mutational clusters onto structural proteome, designs drugs optimized for druggable pocket, and identifies druggable-pocket and cancer-driving mechanisms. Nested is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Nest-1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.